Addiction research. Ibogaine therapy: a 'vast, uncontrolled experiment'.
Vastag
Brian
B
D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D002986:Clinical Trials as Topic; D004298:Dopamine / Q000378:metabolism; D051100:Glial Cell Line-Derived Neurotrophic Factor; D018698:Glutamic Acid / Q000378:metabolism; D006212:Hallucinations / Q000139:chemically induced; D006213:Hallucinogens; D006801:Humans; D007050:Ibogaine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D009414:Nerve Growth Factors / Q000378:metabolism; D011978:Receptors, Nicotinic / Q000378:metabolism; D011957:Receptors, Opioid / Q000378:metabolism; D012701:Serotonin / Q000378:metabolism; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology; D019966:Substance-Related Disorders / Q000188:drug therapy*
D004298:Dopamine; D051100:Glial Cell Line-Derived Neurotrophic Factor; D018698:Glutamic Acid; D006213:Hallucinogens; D007050:Ibogaine; D009414:Nerve Growth Factors; D011978:Receptors, Nicotinic; D011957:Receptors, Opioid; D012701:Serotonin; D017367:Selective Serotonin Reuptake Inhibitors; C495039:GDNF protein, human; C094385:noribogaine; C103345:18-methoxycoronaridine